imatinib mesylate has been researched along with Graft-Versus-Host Disease in 93 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 38 (40.86) | 29.6817 |
| 2010's | 44 (47.31) | 24.3611 |
| 2020's | 11 (11.83) | 2.80 |
| Authors | Studies |
|---|---|
| Agha, IY; Aljurf, M; Blok, HJ; Browne, P; Chalandon, Y; De Witte, T; Ganser, A; Hayden, P; Helbig, G; Hoek, J; Iacobelli, S; Kroeger, N; Masouridi-Levrat, S; Morozova, E; Nagler, A; Niittyvuopio, R; Olavarria, E; Passweg, J; Reményi, P; Robin, M; Sengeloev, H; Snowden, JA; Van Gorkom, G; Wallet, HL | 1 |
| Badell Serra, I; de la Fuente Regaño, L; Díaz de Heredia Rubio, C; Galán Gómez, V; González Vicent, M; Isabel Pascual Martínez, A; López Duarte, M; María Fernández, J; María Pérez Hurtado, J; Pérez-Martínez, A; Rodríguez Villa, A; Soledad Maldonado Regalado, M | 1 |
| Alsuliman, T; Beguin, Y; Bulabois, CE; Chevallier, P; Coiteux, V; Daguindau, E; Forcade, E; François, S; Guillerm, G; Labreuche, J; Magro, L; Srour, M; Turlure, P; Yakoub-Agha, I | 1 |
| Abduljalil, O; Gerbitz, A; Kim, DDH; Kumar, R; Lam, W; Law, A; Linn, SM; Lipton, J; Mattsson, J; Michelis, FV; Novitzky-Basso, I; Pasic, I; Viswabandya, A | 1 |
| Aron, J; Avery, P; Morton, S; Terry, C | 1 |
| Alsuliman, T; Beauvais, D; Coiteux, V; Gauthier, J; Lionet, A; Magro, L; Srour, M; Yakoub-Agha, I | 1 |
| Abdel-Azim, H; Aljurf, M; Alyea, E; Ancheta, R; Bacher, U; Bajel, A; Beitinjaneh, A; Cahn, JY; Cerny, J; Chaudhri, NA; Daly, A; DeFilipp, Z; Gadalla, S; Gale, RP; Ganguly, S; Gerds, A; Grunwald, MR; Hamadani, M; Hashmi, S; Hildebrandt, GC; Hossain, N; Hsu, JW; Hu, ZH; Inamoto, Y; Juckett, MB; Kalaycio, M; Kamble, R; Kharfan-Dabaja, MA; Lazarus, H; Liesveld, J; Litzow, M; Liu, Y; Nishihori, T; Olsson, R; Popat, U; Ramanathan, M; Reshef, R; Rowe, JM; Saber, W; Savani, BN; Savoie, ML; Schouten, HC; Schultz, KR; Seo, S; Snyder, D; Sobecks, R; Solh, M; Szer, J; Ustun, C; Yared, J | 1 |
| Baird, K; Booher, S; Comis, LE; Cowen, EW; Ho, PS; Joe, GO; Mitchell, SA; Pavletic, SZ; Rosenthal, EA | 1 |
| Bagnasco, F; Castagnola, E; Faraci, M; Giardino, S; Girosi, D; Lanino, E; Michele Magnano, G; Olcese, R; Pierri, F; Ricci, E | 1 |
| Gao, X; Huang, X; Joshi, N; Luo, L; Shamseddine, N | 1 |
| Bermudez, A; Costilla Barriga, L; Ferrá Coll, C; López Corral, L; Lopez Godino, O; Márquez-Malaver, F; Martín, G; Martinez, C; Móles-Poveda, P; Ortí, G; Parra Salinas, I; Rifon, J; Zudaire Ripa, MT | 1 |
| An, HY; Baek, HJ; Choi, JY; Hong, KT; Kang, HJ; Kim, BK; Kim, H; Kook, H; Lee, JM; Shin, HY | 1 |
| Botella-Estrada, R; de Unamuno, B; Molés-Poveda, P; Montesinos, P; Piñana, JL; Sahuquillo, A; Sanz-Caballer, J | 1 |
| Ferrándiz-Pulido, C | 1 |
| Battezzi, A; Bernardinetti, M; Bove, T; Parisella, L; Tomasino, S; Vetrugno, L | 1 |
| Bacigalupo, A; Bresciani, P; Cimminiello, M; Coluzzi, S; Corradini, P; Fedele, R; Gabrielli, A; Leoni, P; Mordini, N; Nuccorini, R; Olivieri, A; Olivieri, J; Onida, F; Pane, F; Pascale, S; Patriarca, F; Pavone, E; Poloni, A; Selleri, C; Svegliati, S | 1 |
| Fancher, KM; Green, MR; Newton, MD | 1 |
| Ahlberg, L; Åström, M; Hägglund, H; Hallböök, H; Hulegårdh, E; Karbach, H; Karlsson, K; Markuszewska, A; Persson, I | 1 |
| Akhtari, M; Armitage, JO; Bhatt, VR; Bociek, RG; Dave, BJ; Kessinger, A; Sanger, WG; Sanmann, JN; Yuan, J | 1 |
| Liu, H; Sun, Z; Tang, B; Wang, L; Yao, W; Zhang, L; Zheng, C; Zhu, X | 1 |
| Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH | 1 |
| Baird, K; Booher, S; Comis, LE; Cowen, EW; Figg, WD; Flanders, KC; Hakim, FT; Joe, GO; Mitchell, SA; Pavletic, SZ; Rose, JJ; Sarantopoulos, S; Steinberg, SM; Takebe, N; Yao, L | 1 |
| Chen, F; Date, H; Ueki, T; Zhang, J | 1 |
| Hu, J; Huang, X; Jiang, H; Jiang, Q; Wu, D; Xu, L; Zhu, H | 1 |
| Arai, S; Chai, X; Chen, GL; Flowers, ME; Green, M; Hyun, TS; Inamoto, Y; Jagasia, MH; Jaglowski, S; Khera, N; Lee, SJ; Martin, PJ; Mayer, SA; Miklos, DB; Palmer, J; Pidala, J; Pusic, I; Sarantopoulos, S; Shulman, HM; Storer, BE; Wood, WA | 1 |
| Akashi, K; Eto, T; Henzan, H; Ito, Y; Kamimura, T; Kato, K; Miyamoto, T; Nagafuji, K; Ohno, Y; Takase, K; Takashima, S; Techima, T; Yoshida, S; Yoshimoto, G | 1 |
| Arnan, M; Duarte, RF; Muniesa, C; Parody, R; Patino, B; Sánchez-Ortega, I; Servitje, O; Sureda, A | 1 |
| Eskazan, AE | 1 |
| Baron, F; Beguin, Y; Belle, L; Binsfeld, M; Delvenne, P; Drion, P; Ehx, G; Fransolet, G; Hannon, M; Somja, J | 1 |
| Bruno, B; Catteau, B; Coiteux, V; Jouet, JP; Magro, L; Yakoub-Agha, I | 1 |
| Carreras, E; Fernández-Avilés, F; Martínez, C; Mascaró, JM; Moreno-Romero, JA; Rovira, M | 1 |
| Kolb, HJ | 1 |
| Gronkowska, A; Lakomy, M; Michalewska, B; Pogorzala, M; Rokicka, M; Styczynski, J; Tomaszewska, A; Torosian, T; Wiktor-Jedrzejczak, W; Wysocki, M | 1 |
| Apostolidis, J; Baltadakis, I; Evangelou, K; Gorgoulis, VG; Harhalakis, N; Karakasis, D; Papadakis, V; Sfikakis, PP | 1 |
| Cowen, EW | 1 |
| Catteau, B; Chevallier, P; Coiteux, V; Jouet, JP; Magro, L; Mohty, M; Terriou, L; Yakoub-Agha, I | 1 |
| Bacigalupo, A; Balduzzi, A; Cimminiello, M; Gabrielli, A; Gini, G; Leoni, P; Locatelli, F; Mordini, N; Olivieri, A; Raimondi, R; Sanna, A; Zecca, M | 1 |
| Adil, SN; Kumar, S; Masood, N | 1 |
| Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC | 1 |
| Ahlborn, R; Buchholz, S; Diedrich, H; Eder, M; Ganser, A; Kamal, H; Stadler, M | 1 |
| Deng, D; Lai, Y; Li, Q; Liang, Y; Liu, R; Luo, J; Ma, J; Peng, Z; Schwarzenberger, P; Shi, L; Yang, J; Zhou, J; Zhou, Y | 1 |
| Beyer, C; Distler, JH; Distler, O | 1 |
| Abe, D; Fujisawa, S; Hoshino, T; Kanamori, H; Kanda, Y; Maruta, A; Nakaseko, C; Nakasone, H; Okamoto, S; Sakura, T; Takahashi, S; Takasaki, H; Usuki, K; Yano, S; Yokota, A | 1 |
| Eapen, M | 1 |
| Apperley, JF; Cross, NC; Melo, JV; Score, J; Sobrinho-Simões, M; Wilczek, V | 1 |
| Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, DH; Liu, KY; Liu, YR; Wang, Y; Xu, LP | 1 |
| Arthur, C; Bartley, PA; Branford, S; Dang, P; Field, C; Filshie, RJ; Grigg, AP; Hughes, TP; Melo, JV; Mills, AK; Ross, DM; Schwarer, AP; Seymour, JF; Slader, C | 1 |
| Akiyama, H; Atsuta, Y; Hatta, Y; Kanamori, H; Kawa, K; Kimura, Y; Matsuo, K; Miyazaki, Y; Mizuta, S; Morishima, Y; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Sakamaki, H; Ueda, Y; Usui, N; Yagasaki, F; Yujiri, T | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Du, W; Miharu, M; Osumi, T; Shimada, H; Takahashi, T; Tanaka, R | 1 |
| Cai, Z; Han, X; He, J; Huang, H; Li, L; Lin, M; Luo, Y; Shi, J; Tan, Y; Xie, W; Ye, X; Zhao, Y; Zheng, Y | 1 |
| Martínez, C | 1 |
| Chauncey, TR; Flowers, ME; Georges, GE; Lange, T; Langston, AA; Laport, GG; Maloney, DG; Maris, MB; Ram, R; Sandmaier, BM; Storb, R; Storer, B; Woolfrey, A | 1 |
| Cuzzola, M; Dattola, A; Fedele, R; Iacopino, P; Irrera, G; Martino, M; Messina, G | 1 |
| Loughran, TP; Yang, J | 1 |
| Arai, S; Chen, GL; Cheng, EC; Flowers, ME; Johnston, LJ; McMillan, A; Miklos, DB; Otani, JM; Qiu, J; Shizuru, JA | 1 |
| Balduzzi, A; Berger, M; Fagioli, F; Favre, C; Lanino, E; Lo Nigro, L; Locatelli, F; Masetti, R; Messina, C; Prete, A; Rabusin, M; Rognoni, C; Zecca, M | 1 |
| Arnan, M; Duarte, RF; Manresa, F; Ortí, G; Peralta, T; Sánchez-Ortega, I; Servitje, O | 1 |
| Ahn, KW; Akpek, G; Aljurf, M; Artz, A; Cahn, JY; Cairo, M; Chen, YB; Cooper, B; de Lima, M; Deol, A; Giralt, S; Gupta, V; Khoury, HJ; Kohrt, H; Lazarus, HM; Lewis, I; Olsson, R; Pedersen, TL; Pidala, J; Pulsipher, M; Savani, BN; Seftel, M; Socié, G; Tallman, M; Ustun, C; Vij, R; Vindeløv, L; Warlick, E; Weisdorf, D | 1 |
| Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, DH; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH; Zhang, YY; Zhao, XY | 1 |
| Brosa, M; Crespo, C; Pérez-Simón, JA; Rodríguez, JM; Sierra, J | 1 |
| Burge, S; Peniket, A; Rodgers, CJ; Scarisbrick, J | 1 |
| Dees, C; Del Galdo, F; Distler, A; Distler, JH; Distler, O; Egberts, F; Palumbo-Zerr, K; Schett, G; Spriewald, BM; Tinazzi, I; Tomcik, M; Vollath, S; Zerr, P | 1 |
| Ahn, HS; Kang, HJ; Kim, H; Kim, MS; Kim, NH; Lee, JW; Park, KD; Shin, HY | 1 |
| Adès, L; Bagot, M; Bouaziz, JD; Bourhis, JH; Dalle, JH; de Masson, A; Micol, JB; Nguyen, S; Peffault de Latour, R; Ribaud, P; Robin, M; Rubio, MT; Rybojad, M; Socié, G; Suarez, F; Wittnebel, S; Xhaard, A; Yakouben, K | 1 |
| Fan, ZP; Huang, F; Jiang, QL; Ling, YW; Liu, QF; Sun, J; Zhai, X; Zhang, FH; Zhang, Y; Zhou, HS | 1 |
| Andersson, PO; Brune, M; Gustavsson, B; Stockelberg, D; Wadenvik, H; Wernstedt, P | 1 |
| Bornhäuser, M; Ehninger, G; Illmer, T; Schaich, M; Schäkel, K | 1 |
| Fujioka, T; Hosen, N; Ikegame, K; Kawakami, M; Kawase, I; Kim, EH; Konaka, Y; Kunitomi, A; Masuda, T; Mukouchi, C; Murakami, M; Nishida, S; Ogawa, H; Oji, Y; Oka, Y; Sugiyama, H; Taniguchi, Y; Tsuboi, A | 1 |
| Hwang, JY; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Kim, YL; Lee, JW; Lee, S; Min, WS; Park, YH | 1 |
| Fujisawa, S; Hatsumi, N; Kishi, K; Miyakoshi, S; Miyawaki, S; Mori, S; Nakajima, H; Oki, M; Sakamaki, H; Sakura, T; Tanaka, Y; Ueyama, J; Yokota, A | 1 |
| Chao, TC; Chen, PM; Chiou, TJ; Hsiao, LT; Lee, MY; Lin, JT; Yang, MH | 1 |
| Chung, NG; Hwang, JY; Kim, CC; Kim, DW; Kim, YJ; Kim, YL; Lee, S; Min, CK | 1 |
| Sato, Y; Tanizawa, Y; Yujiri, T | 1 |
| Alyea, EP; Antin, JH; DeAngelo, DJ; Galinsky, I; Hochberg, EP; Lee, S; Longtine, J; Parekkedon, B; Ritz, J; Soiffer, RJ; Stone, RM | 1 |
| Cho, B; Chung, NG; Chung, YJ; Goh, HG; Han, CW; Jin, JY; Kim, CC; Kim, DW; Kim, HJ; Kim, HK; Kim, JA; Kim, JW; Kim, SH; Kim, TG; Kim, YJ; Kim, YL; Lee, JW; Lee, S; Min, CK; Min, WS; Oh, IH | 1 |
| Douek, DC; Dunbar, CE; Greiner, E; Loré, K; Magnusson, MK; Price, DA; Seggewiss, R; Wiestner, A | 1 |
| Bruno, A; Chunduri, S; Dobogai, LC; Kadkol, S; Rondelli, D | 1 |
| Apperley, JF; Bacigalupo, A; Brune, M; Crawley, C; Gratwohl, A; Juliusson, G; Komarnicki, M; Lalancette, M; Lange, A; Mayer, J; Nagler, A; Niederwieser, D; Passweg, J; Rambaldi, A; Ringden, O; Sierra, J; Szydlo, R; Vitek, A; Zander, A | 1 |
| Balon, J; Giebel, S; Gooley, TA; Hellmann, A; Hołowiecki, J; Kałwak, K; Kruzel, T; Prejzner, W; Szatkowski, D; Wojnar, J; Zaucha, JM | 1 |
| Caplan, SN; Fetni, R; Johnson, NA | 1 |
| Akiyama, H; Kanda, Y; Kasai, M; Kato, S; Yamaguchi, H | 1 |
| Bornhäuser, M; Bunjes, D; Fischer, T; Gschaidmeier, H; Haus, U; Hess, G; Hochhaus, A; Huber, C; Kindler, T; Kobbe, G; Ledderose, G; Schwerdtfeger, R; Siegert, W; Ullmann, AJ; Wassmann, B | 1 |
| de-Souza, C; García-Ruiz-Esparza, MA; Giralt, S; Gómez-Almaguer, D; Gutiérrez-Aguirre, CH; Karduss, A; Manzano, C; Miranda, E; Morales-Toquero, A; Ruiz-Argüelles, GJ; Sumoza, A; Vela-Ojeda, J | 1 |
| Benson, DM; Blum, W; Grady, T; Kennedy, MS; Krugh, D; Marcucci, G; O'Donnell, L; Williams, JD | 1 |
| Bornhäuser, M; Ehninger, G; Fruehauf, S; Kiehl, MG; Kienast, J; Kröger, N; Mundhenk, P; Sayer, HG; Schafer-Eckart, K; Scheid, C; Schwerdtfeger, R; Stelljes, M; Theuser, C; Wandt, H; Zander, AR | 1 |
| Apperley, JF; Khorashad, JS; Marin, D; Olavarria, E; Perz, JB | 1 |
| Azhipa, O; Friedman, TM; Goldberg, SL; Hsu, JW; Korngold, R; Pecora, AL; Preti, RA; Rowley, SD; Tkachuk, Y; Zilberberg, J | 1 |
| Chen, H; Han, W; Huang, XJ; Liu, DH; Liu, KY; Xu, LP | 1 |
| Dobrovolna, M; Formankova, R; Ivaskova, E; Keslova, P; Kobylka, P; Krol, L; Michalova, K; Moravcova, J; Navratilova, J; Sedlacek, P; Stary, J; Vavra, V; Zemanova, Z | 1 |
| Copland, M; Crawley, C; Godden, J; Heaney, NB; Holyoake, TL; McQuaker, IG; Parker, AN; Shepherd, P; Smith, GM; Stewart, K | 1 |
| Brunstein, CG; Mcglave, PB | 1 |
| Gschaidmeier, H; Hoelzer, D; Klein, SA; Martin, H; Ottmann, OG; Pfeifer, H; Scheuring, U; Wassmann, B | 1 |
7 review(s) available for imatinib mesylate and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant | 2016 |
Graft-versus-leukemia effects of transplantation and donor lymphocytes.
Topics: Antineoplastic Agents; Benzamides; Blood Donors; Graft vs Host Disease; Graft vs Host Reaction; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Immune Tolerance; Immunotherapy, Adoptive; Leukemia; Lymphocyte Transfusion; Lymphocytes; Piperazines; Pyrimidines; Transplantation Immunology; Tumor Escape | 2008 |
Old disease, new targets. Part-II, haematological malignancies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Drug Costs; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Time Factors | 2009 |
[Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].
Topics: Adrenal Cortex Hormones; Animals; Benzamides; Calcineurin Inhibitors; Chronic Disease; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Transplantation, Homologous; Treatment Outcome | 2010 |
More than skin deep? Emerging therapies for chronic cutaneous GVHD.
Topics: Antibodies, Monoclonal, Murine-Derived; Benzamides; Chronic Disease; Graft vs Host Disease; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Rituximab; Skin Diseases; Ultraviolet Therapy | 2013 |
[Present status in hematopoietic stem cell transplantation (discussion)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzamides; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Opportunistic Infections; Piperazines; Pyrimidines; Rituximab; Tissue and Organ Procurement; Tissue Donors; Transplantation Conditioning; Transplantation Immunology | 2005 |
The biology and treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Survival Analysis | 2001 |
20 trial(s) available for imatinib mesylate and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone
Topics: Bone Marrow Transplantation; Graft vs Host Disease; Humans; Imatinib Mesylate; Prospective Studies; Pyrimidines; Salvage Therapy; Steroids; Treatment Outcome | 2023 |
Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-Host Disease.
Topics: Adolescent; Adult; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Mycophenolic Acid; Prospective Studies; Quality of Life; Steroids; Young Adult | 2021 |
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Autoantibodies; Benzamides; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Lymphoproliferative Disorders; Male; Middle Aged; Monitoring, Physiologic; Myeloproliferative Disorders; Piperazines; Prednisolone; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Severity of Illness Index; Survival Rate; Time Factors | 2013 |
Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study.
Topics: Adult; Aged; Autografts; Benzamides; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Sweden; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Drug Administration Schedule; Fasciitis; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Joints; Leukemia; Male; Middle Aged; Mycophenolic Acid; Pilot Projects; Prednisone; Range of Motion, Articular; Recurrence; Skin Diseases; Tacrolimus; Transplantation, Homologous | 2015 |
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.
Topics: Adult; Aged; B-Lymphocytes; Cross-Over Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Prospective Studies; Rituximab; Sclerosis; Skin Diseases; Tumor Necrosis Factor Receptor Superfamily, Member 7; Young Adult | 2016 |
Imatinib for refractory chronic graft-versus-host disease with fibrotic features.
Topics: Adolescent; Adult; Benzamides; Child; Female; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Intestinal Diseases; Lung Diseases; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy; Skin Diseases; Survival Analysis; Treatment Outcome | 2009 |
Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease.
Topics: Adult; Benzamides; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Lung Diseases; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Treatment Outcome; Young Adult | 2009 |
Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrow transplantation for that disease?
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Child; Disease Progression; Disease-Free Survival; Drug Therapy; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Benzamides; Child; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Benzamides; Chronic Disease; Disease-Free Survival; Drug Resistance; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2011 |
Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.
Topics: Adult; Benzamides; Bone Marrow Transplantation; Chronic Disease; Dasatinib; Drug Resistance; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Sclerosis; Skin Diseases; Thiazoles; Transplantation, Homologous | 2012 |
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
Topics: Adolescent; Adult; Benzamides; Child; Child, Preschool; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.
Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2004 |
Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Incidence; Leukocyte Transfusion; Life Tables; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.
Topics: Acute Disease; Adolescent; Adult; Benzamides; Combined Modality Therapy; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Prospective Studies; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Transplantation, Homologous | 2004 |
Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bilirubin; Blood Platelets; Creatinine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Male; Middle Aged; Neutrophils; Piperazines; Pyrimidines; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2005 |
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Topics: Adult; Antineoplastic Agents; Benzamides; Feasibility Studies; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maximum Tolerated Dose; Piperazines; Polymerase Chain Reaction; Prospective Studies; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Outcome | 2005 |
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Haplotypes; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia; Lymphocyte Transfusion; Male; Methotrexate; Mitoxantrone; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Tissue Donors; Treatment Outcome | 2007 |
Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia.
Topics: Adult; Benzamides; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Length of Stay; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Virus Activation | 2008 |
66 other study(ies) available for imatinib mesylate and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Pa
Topics: Dasatinib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Prospective Studies; Protein Kinase Inhibitors | 2022 |
Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic Hematopoietic stem cell Transplantation in Philadelphia acute lymphoblastic leukemia.
Topics: Acute Disease; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2022 |
A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes.
Topics: Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Retrospective Studies; Treatment Outcome | 2023 |
Imatinib-induced pericardial effusion in a child.
Topics: Child; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Pericardial Effusion; Protein Kinase Inhibitors | 2019 |
The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease.
Topics: Adrenal Cortex Hormones; Adult; Chronic Disease; Combined Modality Therapy; Drug Resistance; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Male; Methoxsalen; Middle Aged; Photopheresis; Photosensitizing Agents; Protein Kinase Inhibitors; Retrospective Studies; Sclerosis; Treatment Outcome; Young Adult | 2020 |
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2020 |
Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.
Topics: Adolescent; Adult; Child; Chronic Disease; Clinical Trials, Phase II as Topic; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Motor Skills; Quality of Life; Sclerosis; Young Adult | 2020 |
Imatinib melylate as second-line treatment of bronchiolitis obliterans after allogenic hematopoietic stem cell transplantation in children.
Topics: Adolescent; Bronchiolitis Obliterans; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Incidence; Male; Prognosis; Transplantation, Homologous | 2020 |
Continuation of systemic treatments and outcomes for patients with chronic graft-versus-host disease in the USA.
Topics: Adult; Chronic Disease; Female; Graft vs Host Disease; Health Care Costs; Health Resources; Humans; Imatinib Mesylate; Insurance Claim Review; Male; Medication Adherence; Middle Aged; MTOR Inhibitors; Outcome Assessment, Health Care; Photopheresis; Retrospective Studies; Time-to-Treatment; United States | 2021 |
Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH).
Topics: Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Retrospective Studies; Steroids | 2021 |
Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
Topics: Adolescent; Adult; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Scleroderma, Localized; Treatment Outcome; Young Adult | 2018 |
Imatinib: A New Tool for the Management of Chronic Sclerodermatous Graft-Vs-Host Disease.
Topics: Chronic Disease; Graft vs Host Disease; Humans; Imatinib Mesylate; Scleroderma, Localized | 2018 |
Cardiac tamponade and graft versus host disease: one more reason to remember.
Topics: Biomarkers; Cardiac Tamponade; Echocardiography; Graft vs Host Disease; Heart Function Tests; Hematopoietic Stem Cell Transplantation; Hemodynamics; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardiocentesis; Treatment Outcome | 2018 |
Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Benzamides; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Imatinib Mesylate; Immunosuppressive Agents; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
[Allo-geneic hematopoietic stem cell transplantation in treatment with T315I mutation of chronic myelogenous leukemia].
Topics: Adult; Allografts; Benzamides; Cord Blood Stem Cell Transplantation; Cyclosporine; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Retrospective Studies; Siblings | 2014 |
Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Acute Disease; Adult; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors | 2015 |
Imatinib for sclerodermatous graft-versus-host disease in lung transplantation.
Topics: Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Lung Transplantation; Protein Kinase Inhibitors; Pulmonary Fibrosis; Young Adult | 2015 |
Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Topics: Adolescent; Adult; Aged; Dasatinib; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2015 |
Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome‑positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dasatinib; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Young Adult | 2015 |
Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Sclerosis; Treatment Outcome | 2016 |
Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors | 2016 |
Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Graft vs Host Disease; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Scleroderma, Localized; T-Lymphocyte Subsets; T-Lymphocytes | 2016 |
Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Female; Fibroblasts; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Scleroderma, Systemic; Transforming Growth Factor beta; Transplantation, Homologous; Treatment Outcome | 2008 |
Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
Topics: Adolescent; Benzamides; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Localized | 2008 |
Fatal combined immune hemolytic anemia after double cord blood transplantation in imatinib-resistant CML.
Topics: Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Antibodies, Anti-Idiotypic; Antineoplastic Agents; Benzamides; Cord Blood Stem Cell Transplantation; Cyclosporine; Drug Resistance, Neoplasm; Fatal Outcome; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Splenectomy; Transfusion Reaction; Transplantation Conditioning; Young Adult | 2009 |
Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?
Topics: Benzamides; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Scleroderma, Systemic; Treatment Outcome | 2009 |
A call for more dermatologic input into chronic graft-vs-host disease clinical trials.
Topics: Benzamides; Chronic Disease; Clinical Trials as Topic; Dermatology; Graft vs Host Disease; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Localized; Skin Diseases | 2009 |
Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Benzamides; Child, Preschool; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Salvage Therapy; Sclerosis; Young Adult | 2009 |
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reoperation; Retrospective Studies; Risk; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Disease Models, Animal; Drugs, Investigational; ErbB Receptors; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Mixed Connective Tissue Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pulmonary Fibrosis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Scleroderma, Systemic; Thiazoles | 2010 |
Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Bone marrow or peripheral blood.
Topics: Adult; Benzamides; Bone Marrow Transplantation; Disease-Free Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Survival Analysis | 2010 |
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Stem Cell Transplantation; Young Adult | 2010 |
Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Benzamides; Busulfan; Child; Cyclophosphamide; Female; Fusion Proteins, bcr-abl; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precision Medicine; Protein-Tyrosine Kinases; Pyrimidines; Risk; RNA, Messenger; Siblings; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; DNA, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2010 |
Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cause of Death; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation, Homologous; Treatment Outcome | 2011 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD.
Topics: Adolescent; Benzamides; Bone Marrow Transplantation; Chronic Disease; Fasciitis; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous | 2012 |
Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Topics: Adult; Benzamides; Blast Crisis; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease Progression; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2011 |
Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease.
Topics: Benzamides; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Large Granular Lymphocytic; Piperazines; Pyrimidines; Time Factors; Treatment Outcome | 2011 |
Potential clinical application of imatinib mesylate in patients with leukemic large granular lymphocytes.
Topics: Benzamides; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Large Granular Lymphocytic; Piperazines; Pyrimidines | 2011 |
Allogeneic hematopoietic stem cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in children and adolescents: a retrospective multicenter study of the Italian Association of Pediatric Hematology and Oncology (AIEOP).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Disease-Free Survival; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Italy; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Retrospective Studies; Secondary Prevention; Transplantation, Homologous; Young Adult | 2012 |
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
Topics: Adult; Aged; Benzamides; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors | 2012 |
Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain.
Topics: Antibodies, Monoclonal, Murine-Derived; Benzamides; Chronic Disease; Computer Simulation; Cost-Benefit Analysis; Drug Costs; Graft vs Host Disease; Health Care Costs; Health Care Rationing; Health Services Needs and Demand; Humans; Imatinib Mesylate; Immunosuppressive Agents; Models, Economic; National Health Programs; Needs Assessment; Photopheresis; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Rituximab; Spain; Time Factors; Treatment Outcome | 2012 |
Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
Topics: Animals; Benzamides; Chronic Disease; Dermis; Disease Models, Animal; Drug Therapy, Combination; Female; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Middle Aged; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic; Signal Transduction | 2012 |
Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD.
Topics: Adolescent; Benzamides; Chronic Disease; Creatinine; Drug Administration Schedule; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Male; Piperazines; Pyrimidines; Scleroderma, Systemic; Time Factors; Treatment Outcome | 2012 |
Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Benzamides; Child; Child, Preschool; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Localized; Scleroderma, Systemic; Skin; Young Adult | 2012 |
The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2013 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Betamethasone; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Vincristine | 2002 |
Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation.
Topics: Benzamides; Fatal Outcome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Steroids; Stevens-Johnson Syndrome; Transplantation, Homologous | 2003 |
Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin.
Topics: Adult; Antineoplastic Agents; Benzamides; Family; Female; Genes, abl; Graft vs Host Disease; Haplotypes; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Biphenotypic, Acute; Methotrexate; Methylprednisolone; Mycophenolic Acid; Pedigree; Piperazines; Pyrimidines; Tacrolimus; Tissue Donors; Transplantation, Homologous | 2003 |
Pulmonary nocardiosis in a patient with CML relapse undergoing imatinib therapy after bone marrow transplantation.
Topics: Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Benzamides; Bone Marrow Transplantation; Bronchiolitis Obliterans; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Nocardia asteroides; Nocardia Infections; Piperazines; Pneumonia, Bacterial; Pyrimidines; Tomography, X-Ray Computed; Transplantation, Homologous; Trimethoprim, Sulfamethoxazole Drug Combination | 2004 |
Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Genes, abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Remission Induction; Transplantation Chimera; Transplantation, Homologous | 2004 |
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetics; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome | 2004 |
Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morbidity; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2004 |
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
Topics: Adaptor Proteins, Signal Transducing; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Benzamides; CD8-Positive T-Lymphocytes; Cell Proliferation; Clinical Trials as Topic; Cytomegalovirus; Dose-Response Relationship, Drug; Genome, Human; Graft vs Host Disease; Graft vs Leukemia Effect; Herpesvirus 4, Human; Humans; Imatinib Mesylate; Immunodominant Epitopes; Interleukin-2; Jurkat Cells; Lectins, C-Type; Leukemia; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Membrane Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Structure, Tertiary; Pyrimidines; Receptors, Antigen, T-Cell; Receptors, Interleukin-2; Sequence Homology, Nucleic Acid; Signal Transduction; Stem Cell Transplantation; Transplantation, Homologous; Up-Regulation; ZAP-70 Protein-Tyrosine Kinase | 2005 |
Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia?
Topics: Benzamides; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines | 2005 |
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.
Topics: Adolescent; Adult; Aged; Benzamides; Bone Marrow Transplantation; Disease Progression; Europe; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Risk Factors; Societies, Scientific; Survival Rate; Transplantation Conditioning; Treatment Outcome | 2005 |
Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Central Nervous System Neoplasms; Chronic Disease; Fatal Outcome; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2005 |
The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Blood Component Removal; Child; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
Successful management of sudden, massive immune hemolysis following ABO-incompatible allogeneic PBSCT despite methotrexate GvHD prophylaxis.
Topics: ABO Blood-Group System; Adult; B-Lymphocytes; Benzamides; Blood Group Incompatibility; Graft vs Host Disease; Hemolysis; Humans; Imatinib Mesylate; Immunosuppressive Agents; Male; Methotrexate; Piperazines; Pyrimidines; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Outcome | 2005 |
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Graft vs Host Disease; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Retrospective Studies; Stem Cell Transplantation; Time Factors; Transplantation, Homologous | 2006 |
Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation.
Topics: Adult; Animals; Antilymphocyte Serum; Benzamides; Blast Crisis; Bone Marrow Transplantation; Cell Lineage; Combined Modality Therapy; Female; Gene Rearrangement, T-Lymphocyte; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Lymphocyte Depletion; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Rabbits; Remission Induction; T-Lymphocyte Subsets; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
Prognosis of pediatric patients transplanted for Ph+ chronic myeloid leukemia in the period from 1989 to 2006 in the Czech Republic.
Topics: Adolescent; Benzamides; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Pyrimidines; Time Factors | 2008 |
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Marrow Transplantation; Colitis; Combined Modality Therapy; Enzyme Inhibitors; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Immunosuppression Therapy; Interferon-alpha; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Transfusion; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous | 2001 |